CUE
Cue Biopharma, Inc. (NASDAQ)
Healthcare — Biotechnology
Cue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases. It also developed the Immuno-STAT platform, which targets disease-specific T cells in vivo without broad immune modulation. The company's lead autoimmune candidate is CUE-401, a bifunctional IL-2 and TGF-B program that is advancing towards Phase 1 development to regulate inflammation and drive Treg-mediated tolerance. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.
Price History
Fundamentals
| Market Cap | $119.04M |
| P/E Ratio (TTM) | - |
| Forward P/E | -59.04 |
| EPS (TTM) | $-4.53 |
| Dividend Yield | - |
| Profit Margin | -59.65% |
| Revenue Growth | 1250.60% |
| ROE | -138.52% |
| Debt/Equity | 15.92 |
| Recommendation | None |
| Analyst Target | $115.00 |
| Analysts | 1 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 50.9 |
| Beta | 2.55 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $41.42 |
| 52-Week Low | $4.98 |
| 50-Day Avg | $25.29 |
| 200-Day Avg | $17.16 |
| Avg Volume | 777.3K |
| Volume | 41.5K |
Performance Analysis
BULLISHCUE shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:05 UTC
Back to Screener Export Report